Rezurock

Active Ingredient(s): Belumosudil Mesylate
FDA Approved: * July 16, 2021
Pharm Company: * KADMON PHARMS LLC
Category: Immunosuppressive

Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD).[1][2] It is in the class of drugs known as serine/threonine kinase inhibitors.[2] Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II).[4] Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediate... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rezurock 200 mg Oral Tablet
NDC: 79802-200
Labeler:
Kadmon Pharmaceuticals, LLC